Simcere Pharmaceutical Group

Simcere Pharmaceutical Group company information, Employees & Contact Information

Simcere Pharmaceutical Group Limited (2096.HK) is a pharmaceutical company driven by innovative R&D and committed to synergistic innovation. It has established the State Key Laboratory of Translational Medicine and Innovative Drug Development and currently boasts four R&D centers in Shanghai, Nanjing, Beijing and Boston. With the commitment to "providing today's patients with medicines of the future", the Company focuses on three therapeutic areas: oncology, central nervous system diseases, and autoimmune diseases, while actively expanding its strategic presence in prospective disease areas with significant clinical needs in the future. Simcere now has six global first-in-class innovative drugs, and is holding leading market shares for its key products in China with its excellent R&D and commercialization capabilities. Its vigorous in-house R&D efforts and extensive R&D collaborations have made it a strategic cooperation partner with international and domestic leading innovative pharmaceutical enterprises, medical institutions and research institutes. Moreover, Simcere has been recognized as one of the “Top 10 Innovative Pharmaceutical Enterprises in China” and “Top 100 Pharmaceutical Manufacturing Enterprises of China” for several consecutive years.

Company Details

Employees
1.12K
Founded
-
Address
玄武大道,
Phone
+025-85566666
Email
si****@****ere.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
南京市玄武区, 江苏
Looking for a particular Simcere Pharmaceutical Group employee's phone or email?

Simcere Pharmaceutical Group Questions

News

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6 - GlobeNewswire

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6 GlobeNewswire

Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement - Yahoo Finance

Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement Yahoo Finance

Quviviq launched in China by Simcere - The Pharma Letter

Quviviq launched in China by Simcere The Pharma Letter

NextCure advances ADC pivot with $745M deal for Simcere's phase 1 drug - Fierce Biotech

NextCure advances ADC pivot with $745M deal for Simcere's phase 1 drug Fierce Biotech

Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China - BioSpectrum Asia

Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China BioSpectrum Asia

Abbvie and Simcere enter a $1B T-cell engager deal - BioWorld MedTech

Abbvie and Simcere enter a $1B T-cell engager deal BioWorld MedTech

Idorsia-expands Quviiq into China as Simcere receives NDA approval - The Pharma Letter

Idorsia-expands Quviiq into China as Simcere receives NDA approval The Pharma Letter

Simcere Pharmaceutical Group Announces Sponsored Research Agreement with Boston-based Mass General Brigham - Mass General Brigham

Simcere Pharmaceutical Group Announces Sponsored Research Agreement with Boston-based Mass General Brigham Mass General Brigham

Simcere Zaiming will Present 8 Research Abstracts at the 2023 AACR Annual Meeting - PR Newswire

Simcere Zaiming will Present 8 Research Abstracts at the 2023 AACR Annual Meeting PR Newswire

Simcere Pharmaceutical Group Announces Sponsored Research Agreement with Boston-based Mass General Brigham - Business Wire

Simcere Pharmaceutical Group Announces Sponsored Research Agreement with Boston-based Mass General Brigham Business Wire

JPM25: AbbVie pens $1B deal for Simcere’s phase 1 T-cell engager - Fierce Biotech

JPM25: AbbVie pens $1B deal for Simcere’s phase 1 T-cell engager Fierce Biotech

AbbVie secures option to license Simcere's blood cancer drug candidate - Reuters

AbbVie secures option to license Simcere's blood cancer drug candidate Reuters

Simcere receives clearance to investigate a bi-functional fusion protein drug - Drug Target Review

Simcere receives clearance to investigate a bi-functional fusion protein drug Drug Target Review

Kazia Licenses Rights to Paxalisib in Greater China to Simcere, a Leading Chinese Pharmaceutical Company - PR Newswire

Kazia Licenses Rights to Paxalisib in Greater China to Simcere, a Leading Chinese Pharmaceutical Company PR Newswire

Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc - Business Wire

Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc Business Wire

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States - Yahoo Finance

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States Yahoo Finance

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma - PR Newswire

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma PR Newswire

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration - PR Newswire

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration PR Newswire

Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart - PR Newswire

Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart PR Newswire

Aeromics and Simcere Announce Collaboration and License Agreement for AER-271 in Greater China - PR Newswire

Aeromics and Simcere Announce Collaboration and License Agreement for AER-271 in Greater China PR Newswire

Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China - Yahoo Finance

Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China Yahoo Finance

Simcere Pharmaceutical Announces Share Placing and Subscription Agreement - TipRanks

Simcere Pharmaceutical Announces Share Placing and Subscription Agreement TipRanks

Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China - GlobeNewswire

Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China GlobeNewswire

Simcere Zaiming - Massachusetts Biotechnology Council

Simcere Zaiming Massachusetts Biotechnology Council

Aeromics and Simcere Announce the First-In-Human Dosing of Chinese Healthy Volunteers in Simcere's Phase I Study of The SIM0307 (AER-271), A New Drug for Brain Edema - PR Newswire

Aeromics and Simcere Announce the First-In-Human Dosing of Chinese Healthy Volunteers in Simcere's Phase I Study of The SIM0307 (AER-271), A New Drug for Brain Edema PR Newswire

China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke - PR Newswire

China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke PR Newswire

Simcere links up with Connect, pays $21M cash for rights to eczema asset in China - Fierce Biotech

Simcere links up with Connect, pays $21M cash for rights to eczema asset in China Fierce Biotech

NextCure partners with Simcere Zaiming on cancer drug development - Investing.com

NextCure partners with Simcere Zaiming on cancer drug development Investing.com

China’s Simcere Pharmaceutical Advances At Home After Exit From NYSE - Forbes

China’s Simcere Pharmaceutical Advances At Home After Exit From NYSE Forbes

Profit setback for Simcere Pharma in novel drugs quest - thebambooworks.com

Profit setback for Simcere Pharma in novel drugs quest thebambooworks.com

SCR-7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the S -adenosylmethionine-competitive or the methylthioadenosine-cooperative protein arginine methyltransferase 5 inhibitors in methylthioadenos - Wiley Online Library

SCR-7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the S -adenosylmethionine-competitive or the methylthioadenosine-cooperative protein arginine methyltransferase 5 inhibitors in methylthioadenos Wiley Online Library

Simcere's Sanbexin Emerges as Game-Changer: FDA Grants Breakthrough Therapy Designation to Sanbexin for AIS Treatment - BioSpace

Simcere's Sanbexin Emerges as Game-Changer: FDA Grants Breakthrough Therapy Designation to Sanbexin for AIS Treatment BioSpace

Macrophage-derived extracellular vesicles regulate follicular activation and improve ovarian function in old mice by modulating local environment - Wiley Online Library

Macrophage-derived extracellular vesicles regulate follicular activation and improve ovarian function in old mice by modulating local environment Wiley Online Library

Simcere Pharmaceutical seeks China approval for atopic dermatitis treatment - Pharmaceutical Business review -

Simcere Pharmaceutical seeks China approval for atopic dermatitis treatment Pharmaceutical Business review -

FDA Action Update, September 2024: Approvals, Designations, and Clearances - NeurologyLive

FDA Action Update, September 2024: Approvals, Designations, and Clearances NeurologyLive

Simcere Zaiming’s SIM-0609 gains IND clearance for solid tumors - BioWorld MedTech

Simcere Zaiming’s SIM-0609 gains IND clearance for solid tumors BioWorld MedTech

Amgen and Simcere to collaborate on copy biologicals in China - Generics and Biosimilars Initiative

Amgen and Simcere to collaborate on copy biologicals in China Generics and Biosimilars Initiative

Simcere launches project to tackle neurology, oncology challenges - China Daily

Simcere launches project to tackle neurology, oncology challenges China Daily

AbbVie, Simcere Zaiming partner on myeloma treatment SIM0500 - Rare Cancer News

AbbVie, Simcere Zaiming partner on myeloma treatment SIM0500 Rare Cancer News

Simcere Pharma kicks off $461m Hong Kong IPO - GlobalCapital

Simcere Pharma kicks off $461m Hong Kong IPO GlobalCapital

FAST NEWS: Investment Loss Undermines Simcere Pharma’s Profit - thebambooworks.com

FAST NEWS: Investment Loss Undermines Simcere Pharma’s Profit thebambooworks.com

China's Simcere to be taken private by founder - Reuters

China's Simcere to be taken private by founder Reuters

BMS, Simcere Pharma To Co-Develop Orencia® SC In China - Asian Scientist Magazine

BMS, Simcere Pharma To Co-Develop Orencia® SC In China Asian Scientist Magazine

Simcere Acquires China Rights to Three Bi-Specific Immunoncology Drugs - NAI500

Simcere Acquires China Rights to Three Bi-Specific Immunoncology Drugs NAI500

Merck And Simcere Pharma Establish Chinese Joint Venture - Asian Scientist Magazine

Merck And Simcere Pharma Establish Chinese Joint Venture Asian Scientist Magazine

Score Media and Gaming (SCR) Stock Price, News & Analysis - MarketBeat

Score Media and Gaming (SCR) Stock Price, News & Analysis MarketBeat

Top Simcere Pharmaceutical Group Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant